Followers | 283 |
Posts | 1162 |
Boards Moderated | 0 |
Alias Born | 10/04/2020 |
Friday, December 24, 2021 3:07:53 PM
Also thank you for informing me that Oncology Pharma is responsible for raising the money needed to fund those TWO (2) INDs and I might add they have a limited amount of time to do that. Do you know what the deadline date is for that? In my experience of CROs they typically don't perform raising capital to fund INDs although they're know to assist with resource funding.
Again ALL the points you made are spot on, excellent summary that brings everything to light.
Would you care to enlighten me further about what exactly is the role Canary plays if acquired by Regen? Are these people clinical research pharmacologists and/or biochemists?? Do they have expertise in taking candidate drug IPs to Turn Key IND's ready for entrance into clinical trials?? I'm not 100% certain what their exact role is.
Lastly, what applicable benefit did the consultant BRG bring to the table that benefited Regen? What exactly did they do for Regen that helped in the company's market directives?
Thank you in advance and Happy Holidays!
Be well and prosper...
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM